Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ATLAS Therapy in Intermittent Claudication
NCT04800692Phase 1Active, not recruiting
- Start
- Jun 2021
- Primary completion
- Jul 2027
- Modality
- Allosteric Modulators, Metabolically Activated Prodrugs
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of sapropterin in intermittent claudication (IC) and Peripheral Arterial Disease (PAD). Primary endpoint: Nitric Oxide bioavailability at 90 days. Started Jun 2021; status: active, not recruiting.
02
Drugs
sapropterin
03
Conditions
intermittent claudication (IC)Peripheral Arterial Disease (PAD)
Beyond the preview
Go deeper on NCT04800692.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04800692.